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Objectives. We sought to determine whether treatment with
high dose verapamil prevents restenosis in patients at high risk
for reoccurrence after successful percutaneous transluminal cor-
onary angioplasty (PTCA).
Background. Restenosis is the major limitation of PTCA.
Calcium antagonists have demonstrated some potential as inhib-
itors of this process.
Methods. A total of 98 patients with peripheral occlusive
arterial disease (POAD), stable angina pectoris, mild hyperten-
sion and at least one additional risk factor increasing the likeli-
hood of restenosis after angioplasty were selected for this placebo-
controlled, double-blind, randomized trial. Verapamil (240 mg
twice daily) or placebo was taken for 6 months. Efficacy variables
assessed before and after angioplasty and at 6 weeks and 6 months
after PTCA included thickness of the intima/media complex
degree of stenosis, interventricular septal thickness, crurobra-
chial pressure ratios of dorsalis pedis and posterior tibial arter-
ies, distance to claudication and total vessel diameter.
Results. No significant intergroup differences emerged before
or immediately after PTCA. Six weeks after angioplasty, a signif-
icant thickening of the intima/media complex in the treated
vascular segment of 14.3% occurred in the placebo group versus
0% among verapamil patients (p < 0.01). At 6 months, the
intima/media thickness was 35.7% greater in the placebo group
but had decreased by 14.3% in the verapamil group (p < 0.001). At
6 months, a marked reduction in septal thickness was observed in
the verapamil group versus that in the placebo group (p < 0.001).
The rate of restenosis was also significantly lower in the verapamil
group (p < 0.001). Few minor side effects were reported.
Conclusions. In patients with POAD at increased risk for
restenosis, the administration of high dose verapamil prevented
recurrent stenosis for 6 months after successful peripheral angio-
plasty and was well tolerated.
(J Am Coll Cardiol 1998;31:1299–305)
©1998 by the American College of Cardiology
The efficacy and safety of percutaneous transluminal coronary
angioplasty (PTCA) in patients with peripheral occlusive arte-
rial disease (POAD) has reached an impressive degree of
technical perfection. Depending on the site and complexity of
the lesion or lesions involved, primary success rates for this
procedure are high. However, the subsequent prognosis of
patients who have undergone PTCA for POAD depends to a
large extent on the avoidance of restenosis—the major limita-
tion of this procedure.
It is now generally accepted that the proliferation of smooth
muscle cells in the media of the vessel walls, and their
subsequent migration into the intima, is responsible for the
development of restenosis (1). During the past few years, a
number of experimental studies (1–8) have demonstrated that
calcium antagonists have antiatherogenic properties and could
eventually be useful in preventing restenosis. However, initial
clinical trials (9–11) failed to show convincing evidence that
such agents as diltiazem and nifedipine were able to decrease
the restenosis rate after successful PTCA. By contrast, a recent
trial (12) using high dose verapamil showed a beneficial effect
for patients at high risk of recurrent coronary obstruction. We
therefore sought to determine whether such a treatment
regimen would also prevent restenosis in patients with POAD
after primary successful PTCA.
Methods
Patients. During the recruitment period between January
1993 and September 1995, 98 patients with stage IIb Fontaine
POAD (walking distance ,200 m on the treadmill at 4 km/h,
10° uphill gradient) and concomitant stable angina pectoris
associated with both chronic ischemic heart disease and mild
hypertension underwent PTCA at our hospital. The diagnosis
of POAD was based on the use of arterial angiography and
color-coded duplex ultrasound. Initially all patients had occlu-
sions (diameter #5 cm) or subtotal stenoses in the distal
superficial femoral artery that were present for .6 months.
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Chronic ischemic heart disease was diagnosed by coronary
angiography and myocardial scintigraphy.
For inclusion in the trial, the following criteria were ap-
plied: 1) primary success of PTCA treatment ($30% reduction
of initial lumen constriction); 2) written informed consent; and
3) at least one of six risk factors predictive for restenosis,
including diabetes mellitus, hyperlipoproteinemia, initial sub-
total or total vascular occlusion of the dilated segmented,
eccentric stenosis, residual stenosis of at least 30% or stenosis
localized in the distal superficial femoral artery. Patients with
a history of pelvic stenoses or occlusions; previous adjuvant
therapy with calcium antagonists or with beta-adrenergic
blocking agents; age .75 years; earlier revascularization of the
same area; serious concomitant diseases; first-, second- or
third-degree atrioventricular block; or sinoatrial block were
excluded from participation. Other grounds for exclusion were
diseases of the supporting or connective tissues, limiting the
distance a patient could walk without pain; moderate arterial
hypertension with systolic blood pressure .170 mm Hg; and
diastolic .95 mm Hg. Finally, patients requiring stent treat-
ment for large anatomic segments or elastic stenoses could not
participate in the trial.
Study design. On meeting the inclusion criteria, patients
were randomly assigned to receive either the active treatment
or placebo under double-blind conditions. PTCA was per-
formed using the Seldinger technique with a 5F balloon
catheter 4 cm in length and either 5 or 6 mm in diameter
(Cordis). The diameter of the balloon was chosen according to
the patent upstream or downstream segment of the vessel. As
basic medication after angioplasty, patients were administered
300 mg of acetylsalicylic acid, 80 mg of isosorbide dinitrate
(one depot tablet for 6 months) and 600 mg of naftidrofuryl
(3 3 200 mg, Lipha, Essen, Germany) each day. The latter is
a serotonin 5-hydroxytryptamine (HT2) receptor antagonist
agent with vasoactive and rheologic properties. Depending on
their randomization, patients were also given identically ap-
pearing tablets of either 240 mg of verapamil (480 mg/day) or
placebo, to be taken twice daily. The study protocol was
approved by the local ethics committee of the University of
Dresden. All patients gave their written informed consent to
participate.
Efficacy criteria. Various examinations were performed
before and immediately after and at 6 weeks and 6 months
after PTCA to assess the possible effect of the test medication
in preventing restenosis.
Degree of stenosis. To determine the degree of stenosis,
angiographic examinations were performed transfemorally us-
ing the Seldinger technique with an image intensifier and a
closed-circuit television system. Calculation of the degree of
stenosis was performed using the following equation: Percent
stenosis 5 1 2 (a/A 3 b/B) 3 100, where a is the greatest
constriction of the lumen (mm) in the anteroposterior projec-
tion; b is the greatest constriction of the lumen (mm) in the
lateral projection; A is the normal diameter of the lumen in the
anteroposterior projection; and B is the normal diameter of
the lumen in the lateral projection. On the basis of percent
stenosis, the vessel was classified according to one of six
pathologic stages: I 5 normal; II 5 plaques (stenosis 1% to
25%); III 5 mild (stenosis 26% to 50%); IV 5 severe (stenosis
51% to 75%); V 5 very severe (stenosis 76% to 99%); VI 5
occlusion. The degree of stenosis was also measured using
color-coded duplex ultrasound.
Layer thickness. Color-coded duplex ultrasound was used
to determine the thickness of the intima/media complex. The
equipment used was a Sonos 1000, Hewlett-Packard 7.5/5-
MHz linear probe. The examination was evaluated by two
independent experts in blinded manner as to which group the
patient belonged. The utmost care was taken to perform the
ultrasound measurements under identical conditions to
achieve the maximal degree of accuracy in the analyses. To
reliably sample the same arterial segment over time, the
participating investigators consistently measured layer thick-
ness from the midpoint of the popliteal gap. In separate
experiments with three observers and four repeated measures
of layer thickness for each of 36 patients, we determined
intraobserver variability to be 3.1% and interobserver variabil-
ity 5.9% of total variance. The total diameter of the vessel was
measured after electrocardiographic stimulation. Ultrasound
imaging of the common and superficial femoral arteries up to
the proximal portion of the popliteal artery was performed
with the patient in the supine position.
The artery was continuously imaged by pushing the trans-
ducer slowly along the course of the vessel in all segments.
Occlusions that were shorter than the width of the transducer
(,5 cm) were determined directly using the color stop and
refilling the arteries, which was recordable with color coding
with the aid of freely positioned measuring points integrated
into the equipment. Thickness determinations were made just
above and below the area of the dilated vessel by means of at
least eight individual measurements, which were then aver-
aged.
Septal thickness. Quantitative measurement of the septum
was performed using echocardiography (Sonos 1000, Hewlett-
Packard, 2.5-MHz sectorial probe) during systole by determin-
ing the mean value of at least five echocardiographically
triggered individual measurements.
Crurobrachial ratio of dorsalis pedis. Continuous wave Dopp-
ler ultrasound was used to measure systolic blood pressure in
the arm and in the dorsalis pedis of the leg treated with PTCA.
The ankle/arm SBP ratio was then calculated.
Crurobrachial ratio of posterior tibial artery. SBP was mea-
sured in the arm and posterior tibial artery by means of
continuous wave Doppler ultrasound in the PTCA-treated leg.
The ankle/brachial SBP ratio was then calculated.
Abbreviations and Acronyms
POAD 5 peripheral occlusive arterial disease
PTCA 5 percutaneous transluminal coronary angioplasty
SBP 5 systolic blood pressure
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Distance to claudication. The pain-free walking distance
was measured on the treadmill under standardized conditions
(12° uphill, 4 km/h).
Laboratory tests. These tests included measurement of se-
rum electrolytes, creatinine, transaminases, total cholesterol
and triglycerides and hematologic examinations that were
carried out before and after PTCA and 6 weeks and 6 months
after the procedure.
Statistical analysis. Simple comparisons between mean
values were calculated using t tests: unpaired for group com-
parisons or paired for time point comparisons; U tests were
used for simple between-group comparisons of the degree of
stenosis. Comparison of mean values versus initial values with
a Bonferroni adjustment were performed using repeated mea-
sures covariance analysis and multiple procedures according to
Winer et al. (13). Probabilities were considered statistically
significant for two-tailed tests at the 0.05 level. Unless other-
wise indicated, results are reported as mean value 6 SD.
For a decrease .50% in the rate of restenosis to be
clinically relevant, we estimated that at least 80 patients would
have to be studied. Because high risk patients were selected,
the restenosis rate in the placebo group was expected to exceed
45%. With a presumed dropout rate of 20%, it was necessary
that at least 98 patients enter the study to achieve sufficient
statistical power of at least 90% for a relative effect equal to
60% of the standard deviation of the variables tested.
Results
Baseline characteristics. Table 1 summarizes patient, clin-
ical and angiographic characteristics for each treatment group.
No significant differences emerged between groups at baseline
for any of these characteristics. The mean number of risk
factors for restenosis was 2.7 6 0.6 and 2.5 6 0.9 in the
verapamil and placebo groups, respectively. Baseline values for
layer and septal thickness were also similar in both groups, as
shown in Figures 1 and 2, respectively.
Adherence to study protocol. A total of 48 patients in the
verapamil group and 47 in the placebo group completed the
trial and could be analyzed (Table 2). One verapamil group
and two placebo group patients were placed on other medica-
tion by their physicians during the trial and were therefore
excluded from the efficacy analysis.
In two verapamil group patients, laboratory tests showed a
threefold increase in transaminases above normal baseline
values. However, during further treatment with verapamil, the
elevated transaminases returned to normal levels within 4
weeks, so that these patients were not excluded from the study.
Verapamil-related side effects were limited to one patient who
transiently complained of constipation and dizziness; two
placebo group patients also reported nausea and constipation.
Restenosis. Table 2 shows the changes in mean values for
the two treatment groups over time for percent stenosis,
intima/media thickness, vessel diameter, septal thickness, arte-
rial pressure and the crurobrachial ratios of the dorsalis pedis
and posterior tibial arteries. For these variables, as well as for
the distance to claudication and laboratory tests (data not
shown), no significant intergroup differences were observed on
the side of the treated leg either before or immediately after
PTCA. By contrast, significant differences between verapamil
and placebo emerged (Fig. 1 and 2, Table 2) after 6 weeks of
treatment with regard to intima/media and septal thickness
(both p , 0.01). At 6 months after PTCA, the differences
between verapamil- and placebo-treated patients for these
variables (both p , 0.001), as well as the degree of stenosis
(p , 0.001) and the crurobrachial ratio of the posterior tibial
artery (p , 0.01), became even more apparent. The divergence
Figure 1. Changes in median layer thickness during the trial in placebo
and verapamil group patients. Median values are shown by solid
(verapamil) or dashed lines (placebo); box and whisker plots indicate
the interquartile range (box) as well as the 10th and 90th percentiles
(whiskers).
Table 1. Patient, Clinical and Angiographic Characteristics
Characteristic
Placebo
Group
Verapamil
Group
Patient related
Age (yr) 64.7 6 5.6 63.3 6 6.9
Men/Women 35/14 26/23
Risk factors
Diabetes 22 23
Hyperlipoproteinimia 36 38
Subtotal/total occlusion 42 40
Eccentric stenosis 6 8
Residual stenosis ($30%) 43 41
Clinical
SBP (mm Hg) 152 6 5.2 150 6 5.6
DBP (mm Hg) 91 6 2.5 90 6 3.9
Smoking 28 30
Distance to claudication (m) 110 6 34.0 100 6 38.5
Duration of POAD (mo) 52 6 14 45 6 18
Concomitant CAD 33 35
Angiographic
No. of lesions treated 49 49
% DS before PTCA 96.7 6 2.1 96.8 6 2.5
% DS after PTCA 39.2 6 7.5 38.5 6 6.9
Data presented are mean value 6 SD or number of patients. CAD 5
coronary artery disease; DBP 5 diastolic blood pressure; DS 5 diameter
stenosis; POAD 5 peripheral occlusive arterial disease; PTCA 5 percutaneous
transluminal coronary artery disease; SBP 5 systolic blood pressure.
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between groups tended toward significance for the crurobra-
chial ratio of the dorsalis pedis (p 5 0.06). Laboratory vari-
ables were unaffected after 6 months.
The decrease in septal thickness was also related to a mean
decrease in arterial blood pressure (Table 2). After 6 months,
a positive correlation emerged in the verapamil group between
septal chamber geometry and mean arterial pressure (r 5 0.85,
p 5 0.01). As seen in Table 2, measurements of total vessel
diameter indicated important post-PTCA enlargements in
both groups, followed by a gradual but diverging decrease
between placebo and verapamil group patients (Table 2). This
difference in vessel diameter became significant at month 6
(p , 0.001). Furthermore, a positive correlation was found
between restenosis and total vessel diameter after 6 months
among placebo patients (r 5 0.93, p 5 0.01) (Table 3).
With regard to disease stage (Table 3), the generally
successful results of PTCA were maintained in the verapamil
group at 6 weeks and at 6 months, with only one patient
showing a regression to occlusion. By contrast, although all 49
placebo group patients were classified as having stage I or II
disease after PTCA, this number decreased to 34 after 6 weeks
and then to 22 after 6 months of placebo treatment.
Discussion
Limits of PTCA. In patients with POAD, PTCA is an
effective procedure, with high initial success rates. Previous
studies have indicated that the primary success rate of periph-
eral arterial dilation of the distal superficial femoral artery is
91%. After PTCA, ;48% of patients have no remaining
stenosis; a further 17% show stenosis ,30%, whereas 34%
have residual stenoses in excess of 30% in the region of the
dilated area (14–16). Thereafter, lumen renarrowing is ob-
Table 2. Intergroup Differences in Efficacy Criteria During Six-Month Trial
Before PTCA After PTCA At 6 wk At 6 mo
No. of patients
Placebo 49 49 48 47
Verapamil 49 49 49 48
% DS
Placebo 96.7 6 2.1 39.2 6 7.5 55.5 6 10.0 69.6 6 12.2
Verapamil 96.8 6 2.5 38.5 6 6.9 46.8 6 14.1 48.0 6 11.5*
Intima/media thickness (mm)
Placebo 1.4 6 0.38 1.4 6 0.42 1.6 6 0.43 1.9 6 0.47
Verapamil 1.4 6 0.35 1.4 6 0.38 1.4 6 0.33* 1.2 6 0.31†
Septal thickness (mm)
Placebo 11.6 6 1.8 11.0 6 1.7 11.9 6 1.8 11.9 6 2.3
Verapamil 11.5 6 1.9 11.6 6 1.7 11.0 6 1.5* 10.2 6 1.1†
Crurobrachial ratio
Dorsalis pedis
Placebo 0.68 6 0.10 0.77 6 0.10 0.75 6 0.09 0.72 6 0.08
Verapamil 0.68 6 0.09 0.77 6 0.09 0.76 6 0.08 0.76 6 0.10
Posterior tibial artery
Placebo 0.67 6 0.10 0.78 6 0.10 0.76 6 0.10 0.70 6 0.10
Verapamil 0.65 6 0.09 0.77 6 0.09 0.77 6 0.11 0.76 6 0.09*
Arterial pressure (mm Hg)
Placebo
SBP 168 6 5.2 170 6 6.3 163 6 6.3 165 6 6.5
DBP 101 6 2.5 98 6 3.1 98 6 3.1 97 6 4.4
Verapamil
SBP 170 6 5.6 150 6 5.5† 135 6 5.5† 134 6 5.2†
DBP 100 6 3.9 92 6 4.0† 86 6 4.1† 87 6 4.2†
Total vessel diam (mm)
Placebo 7.1 6 0.5 9.3 6 0.4 8.2 6 0.6 7.5 6 0.3
Verapamil 7.1 6 0.4 9.4 6 0.3 8.5 6 0.6 8.3 6 0.3†
*p , 0.01. †p , 0.001. Data presented are mean value 6 SD, unless otherwise indicated. Abbreviations as in Table 1.
Figure 2. Changes in median septal thickness during the trial in
placebo and verapamil group patients. Symbols as in Figure 1.
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served in a substantial number of patients. According to Strunk
et al. (16), the proportion of open lumens falls to some 77% at
6 months after PTCA and further decreases to 67% after 1
year. The crucial deleterious changes in the vascular wall
generally seem to occur within the first 6 months (16). The
amount and rate of restenosis is also more likely to occur when
such factors as diabetes mellitus, excessive smoking, hypercho-
lesterolemia and a high degree of postoperative residual
stenosis are present (16).
Previous studies with verapamil. In our patients (at in-
creased risk for recurrent obstruction), administration of high
dose verapamil significantly reduced the degree of stenosis and
related variables 6 months after angioplasty compared with
placebo. This result was not unexpected because calcium
antagonists have been shown to possess antiatherogenic prop-
erties both in vitro (1,4) and in vivo (3). The selection of
verapamil for use in the present trial was based on the results
of cell culture experiments that demonstrated stronger anti-
proliferative effects than diltiazem and nifedipine on vascular
smooth muscle cells (1,4) and on intimal cells derived from
early atherosclerotic lesions (17). Administration of a relatively
high dose of verapamil was indicated because data from studies
in a rabbit model (18) had shown that larger doses of calcium
antagonists were required to markedly decrease atherogenic
lesion development. Nevertheless, administration of 240 mg of
verapamil twice daily for 6 months proved safe, with only a few,
mild side effects reported in the active treatment group.
To our knowledge, the present study is the first to evaluate
the use of calcium antagonists for the prevention of restenosis
after PTCA. The vascular protective effect of verapamil ob-
served in this trial was similar to the beneficial effects docu-
mented by Hoberg et al. (12) in which 196 patients at high risk
of coronary obstruction after primary successful coronary
angioplasty were given high dose verapamil for 6 months. Our
results therefore extend the potential efficacy of verapamil
beyond the subgroup of patients undergoing PTCA to those
with POAD as well. However, additional studies are warranted
to ascertain whether the possible benefits of verapamil treat-
ment pertain to patients at a lower risk for restenosis after
PTCA.
Remodeling after PTCA. Various studies (19–21) have
suggested that arterial remodeling in coronary arteries after
balloon angioplasty may contribute substantially to the devel-
opment of restenosis. On measuring total vessel diameter, we
observed a general pattern of vessel enlargement at 6 weeks
after PTCA, followed by a decrease in vessel diameter at 6
months. Late lumen loss was significantly greater among
placebo group patients than verapamil group patients. Our
results parallel the recent observations of Kimura et al. (22)
who found that remodeling after coronary angioplasty was
characterized by early adaptive vessel enlargement, followed
by late constriction. The positive correlation between resteno-
sis and remodeling of total vessel diameter after 6 months
extends the phenomenon of remodeling after coronary angio-
plasty to peripheral arterial vessels as well.
Value of ultrasound measurement. The development of
high resolution 7.5-MHz probes and the use of these B-mode
image intensifiers in Doppler ultrasound equipment have
made it possible to transcutaneously record and structurally
depict the intima and media of large arteries (23–26). The
arterial wall can be visualized on ultrasound as a double
contour, with two hyperechoic lines around a hypoechoic one.
The limits of ultrasound diagnosis are reached in the presence
of large-vessel wall calcifications, where it is difficult to inves-
tigate layer thickness and degree of stenosis because of acous-
tic shadow. A comparison of ultrasound and histologic mea-
surements of arterial wall structures of the common carotid
artery in humans (26) showed good concurrence between the
total thickness of the inner hyperechoic and middle hypoechoic
lines and the actual thickness of the histologically determined
intima/media complex. Similar findings were reported in vitro
in normal and arteriosclerotically altered human aorta prepa-
rations using an 8-MHz ultrasound probe (27).
The good imaging quality of the new ultrasound systems
allows high reproducibility of transcutaneous ultrasound mea-
surements of the intima/media complex (26). For this reason, it
has proven useful to apply ultrasound to determine thickening
of the intima/media complex in the region of the carotid
arteries in studies of hypertension. Using such a technique,
Mayet (28) demonstrated that the use of angiotensin-
Table 3. Change in Degree of Stenosis During Six-Month Trial
Disease
Stage*
Verapamil Placebo
Before PTCA
(n 5 49)
After PTCA
(n 5 49)
At 6 wk
(n 5 49)
At 6 mo
(n 5 48)
Before PTCA
(n 5 49)
After PTCA
(n 5 49)
At 6 wk
(n 5 48)
At 6 mo
(n 5 47)
I 22 20 18 26 17 7
II 23 24 24 20 17 15
III 4 5 5 3 13 19
IV 16 25 1 4
V 33 24
VI 1 2
*I 5 normal; II 5 plaques (stenosis 1% to 25%); III 5 mild (stenosis 26% to 50%); IV 5 severe (stenosis 51% to
75%); PTCA 5 percutaneous transluminal coronary angioplasty. V 5 very severe (stenosis 76% to 99%); VI 5 occlusion.
Data presented are number of patients.
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converting enzyme inhibitors led to a regression of this thick-
ening, even if lipid levels and body mass remained unchanged.
Although restenosis after peripheral arterial dilatation is
significantly associated with endothelial proliferation, these
endothelial changes can only be established angiographically
when the vascular lumen is constricted by at least 30%. To
date, evaluation of early endothelial changes in the region of
the peripheral vessels has only been possible, with difficulty, by
means of intravascular 6F endoultrasound catheters (24). This
limitation has prevented controlled studies from being carried
out to evaluate early endothelial proliferation after angio-
plasty. However, by means of color-coded duplex ultrasound,
the thickness of the layers in this pathologic process can be
measured noninvasively at a significantly earlier stage. In the
present study, staging of stenosis was performed simultaneously
with angiography and (color duplex) ultrasound because only
limited experience with grading stenosis using (color duplex)
ultrasound has been reported (23,26). Our investigations showed
the ultrasound and angiographic results to be similar in determin-
ing the degree of stenosis (results not shown).
Other means for preventing restenosis. Early occlusions
after vascular surgery (within the first week) are primarily due
to arterial thromboses in dissections that have occurred after
dilation (14), whereas progressive stenosis is linked to endo-
thelial proliferation (16). In addition to refining dilation tech-
niques, which are currently also being combined with stent
treatment in the peripheral vessels, drugs that can inhibit
endothelial proliferation have been studied (29). However, the
prevention of restenosis by means of systemically administered
substances, such as antithrombotic, anticoagulant and throm-
bolytics agents; corticosteroids; lipid-reducing drugs; and cyto-
statics agents, could not be shown convincingly to date either
for the coronary arteries or peripheral vessels. More recently,
Voisard et al. (30) observed that the proliferation of the
endothelium in cell cultures was significantly reduced when the
calcium antagonist Trapidil was used. Comparative investiga-
tions of available interventional techniques, such as atherec-
tomy, rotablation or stent implantation, which were all per-
formed in the coronary system, showed that although the
problem of restenosis can be reduced by means of optimal
recanalization techniques, it cannot be eliminated (31).
Conclusions. In patients with POAD who are at increased
risk for restenosis after angioplasty, the administration of
240 mg twice daily of verapamil prevents significant thickening
of the intima/media complex of the treated vascular segment
and appears to limit vessel remodeling. Further trials with
larger numbers of patients are needed to confirm these results
and to determine whether the vascular protective effect of
verapamil extends beyond the 6-month period investigated in
the present study.
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